Investors and Media Better Vision. Healthier Lives.

We are a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, like wet age‐related macular degeneration (wet AMD) and diabetic macular edema (DME), which remain leading causes of vision loss worldwide.

Our lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C/D ‘trap’ inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients.

Sozinibercept has the potential to become the first therapy with wet AMD to live fuller and healthier lives in 20 years.